Ert Pompe denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Issues Duplicate-Therapy Denials for Pompe Disease ERT — and How to Respond

A duplicate-therapy denial means Humana's utilization-review system flagged that the patient appears to already have an ERT product for Pompe disease active on their profile, making the new request look redundant. This most commonly arises during a product transition — when a prescriber is switching from one approved ERT to another — or as a system-level error when a prior authorization is still open on an older product.

This denial is administrative in nature and highly reversible when properly documented. The key is demonstrating that only one product will be administered at a time, that the transition is clinically intentional, and that the new product is not being added on top of an existing regimen but is replacing it.

## Federal Appeal Rights

Humana plans that are non-grandfathered are subject to ACA Section 2719 internal and external review requirements. ERISA Section 503 applies to self-funded employer plans administered by Humana. External review must generally be initiated within four months of the final internal adverse determination. Expedited review is available when the standard timeline would jeopardize health.

## What to Gather

• Prescriber transition letter — a clear statement from the treating physician or metabolic specialist that the patient is transitioning from the prior product to the newly requested product, with the intended stop date for the prior product.
• Active prior-authorization records — pull any open PA for the prior ERT and confirm with Humana whether it remains active or has lapsed.
• Infusion administration records — the most recent infusion logs to show what product was actually administered and when.
• Diagnosis confirmation — genetic testing, enzyme-activity assay, or biopsy confirming Pompe disease, to anchor the medical necessity of the new product.
• Humana's duplicate-therapy policy — obtain the current version of Humana's relevant coverage or utilization-management policy and identify the specific duplicate-therapy criteria.

## Criteria-Mapping Structure

Address Humana's duplicate-therapy definition directly. Confirm in writing that only one ERT product will be dispensed and administered at a time. If the denial stems from an open authorization for the prior product, request that Humana close or void it as part of processing the new request. Provide a timeline: last dose of prior product, intended first dose of new product.

## Process and Timeline

1. Contact Humana's pharmacy or PA team first — many duplicate-therapy flags resolve on a peer-to-peer call once the transition is explained. 2. If a formal denial was issued, file the written internal appeal within the plan's deadline (typically 180 days). 3. Include the transition letter, infusion records, and any request to void the prior PA. 4. If denied internally, proceed to external review within four months of the final determination.